ProMIS Neurosciences is trading 7.4% up at $13.75 after presenting first-in-human evidence that its lead Alzheimer’s antibody, PMN310, successfully engages amyloid-beta oligomer targets.
- The clinical data, presented at the AAIC 2026 conference, provides an encouraging early signal regarding PMN310’s target engagement and development path.
- Shares are rebounding from a sharp decline in the previous session, notably outperforming a broader downturn across the biotech sector today.